Klebsiella pneumoniae is an encapsulated Gram-negative pathogen most commonly known for its involvement in nosocomial and community-acquired infections. These infections can range from pneumonia, urinary tract, and soft tissue infections to more severe conditions such as septicaemia, liver abscess, and sepsis, particularly for the hypervirulent strains. K. pneumoniae is also recognised as one of the six “ESKAPE” pathogens in need for the development of new antimicrobials. Recently, gut microbial colonization by this bacteria has been linked to inflammatory diseases like inflammatory bowel diseases and primary sclerosing cholangitis. As a result, bacterio(phages) have become increasingly relevant as potent therapeutics for treating K. pneumoniae infections and gut colonisations. However, the high variability of the Klebsiella capsule, with up to 79 known capsular (K) types to date, poses a significant challenge for receptor-mediated strategies targeting this pathogen (e.g. vaccine developments and phage therapy). Thus, it is crucial to understand phage-mediated interactions to ensure successful therapeutic applications. Unfortunately, this understanding is currently limited, partly due to the lack of a representative and accessible collection of Klebsiella phages. To this end, our aim was to establish an open-source collection of phages targeting Klebsiella spp. that will be accessible for collaborative and additive research via an online platform. In the initial phase of this project, we isolated and fully characterised 47 phages (the Roth collection) that can target a variety of Klebsiella spp. including some of the most clinically relevant clonal groups (e.g. ST258, ST15, ST14, ST23, ST17, ST86, ST11) and capsular types (e.g. K1 and K2). The phage stocks and associated data will be freely available, and users of the collection are expected to contribute and share data, such as host range information and case/clinical studies. We envision that this open-source collection will significantly contribute to expand our understanding of phage-mediated interactions to facilitate phage therapy applications.